Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cash from Financing Activities: 2023-2025

Historic Cash from Financing Activities for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $94.9 million.

  • Tonix Pharmaceuticals Holding's Cash from Financing Activities rose 121.10% to $94.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.5 million, marking a year-over-year increase of 165.99%. This contributed to the annual value of $134.9 million for FY2024, which is 269.34% up from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's Cash from Financing Activities stood at $94.9 million, which was up 762.92% from $11.0 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's 5-year Cash from Financing Activities high stood at $94.9 million for Q3 2025, and its period low was -$11.5 million during Q1 2023.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Cash from Financing Activities averaged around $29.7 million, with its median value being $11.0 million (2025).
  • Data for Tonix Pharmaceuticals Holding's Cash from Financing Activities shows a peak YoY surged of 23,464.62% (in 2025) over the last 5 years.
  • Tonix Pharmaceuticals Holding's Cash from Financing Activities (Quarterly) stood at $40.7 million in 2023, then skyrocketed by 109.15% to $85.2 million in 2024, then surged by 121.10% to $94.9 million in 2025.
  • Its Cash from Financing Activities stands at $94.9 million for Q3 2025, versus $11.0 million for Q2 2025 and $49.5 million for Q1 2025.